ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Docetaxel

Also written as “docetaxel”, “Taxotere” and “HB1801”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.

Drug pageDocetaxel: every studyMany companies study it; this page follows only the 142 they lead. All 1,164 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2006142 company-led studies, 15 open or runningNext primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only540 open or runningphase 4since Jan 18, 2006Nov 1, 1999none ahead
Hoffmann-La Roche220 open or runningphase 4since Aug 5, 2005Feb 12, 2004none ahead
CSPC Pharmaceutical Groupits history only1511 open or runningphase 3since Apr 20, 2023Mar 10, 2021Dec 16, 2026phase 3 · NCT06747338
Eli Lillyits history only81 open or runningphase 3since Nov 1, 2004Nov 1, 2004May 2027phase 2 · NCT05999994
Pfizerits history only70 open or runningphase 2since Jan 4, 2002Jan 4, 2002none ahead
GlaxoSmithKlineits history only60 open or runningphase 2since Jul 17, 2003Jul 17, 2003none ahead
Amgenits history only40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Merckits history only30 open or runningphase 2since Oct 4, 2007Oct 4, 2007none ahead
Novaceaits history only30 open or runningphase 3since Aug 9, 2002Aug 9, 2002none ahead
Novartisits history only20 open or runningphase 3since Jun 29, 2004Jun 29, 2004none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Feb 12, 2004.

  1. Feb 17, 2009Phase 2 study in Breast NeoplasmsNCT00845910 · 22 enrolled · Taiwan
  2. Jun 24, 2009Phase 1 study in Solid CancersNCT00927589 · 59 enrolled · United States
  3. Jul 6, 2009Phase 2 study in Breast NeoplasmsNCT00934856 · 98 enrolled · United States, France, Spain and more
  4. Aug 21, 2009Phase 2 study in Breast NeoplasmsNCT00964704
  5. May 22, 2013Phase 1 study in Breast NeoplasmsNCT01862081 · 80 enrolled · United States, Belgium, Canada and more
  6. Dec 4, 2013Phase 2 study in Breast NeoplasmsNCT02005549 · 18 enrolled · Austria
  7. Mar 23, 2015Phase 4 study in Breast NeoplasmsNCT02419742 · 110 enrolled · India
  8. Mar 23, 2015Phase 3 study in Breast NeoplasmsNCT02402712 · 418 enrolled · Belgium, Bulgaria, Canada and more
  9. May 13, 2015Phase 4 study in Breast NeoplasmsNCT02445586 · 52 enrolled · India
  10. Nov 12, 2015Phase 1 study in Breast NeoplasmsNCT02605915 · 98 enrolled · United States
  11. Apr 20, 2016Phase 2 study in Breast NeoplasmsNCT02748213 · 225 enrolled · Australia, Brazil, Canada and more
  12. Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03337698 · 314 enrolled · United States, Australia, France and more
  13. May 15, 2020Phase 1 study in Prostatic Neoplasms, Castration-ResistantNCT04404140 · 6 enrolled · France, Italy, Spain and more
  14. Jul 7, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04471428 · 366 enrolled · United States, Australia, Austria and more

TargetBeta

“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

All 22 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04471428Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3CompletedSep 28, 2022366
NCT04404140Prostatic Neoplasms, Castration-Resistant · France, Italy, Spain and more1TerminatedOct 14, 20226
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedOct 14, 2025314
NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more2CompletedMar 2006225
NCT02605915Breast Neoplasms · United States1CompletedNov 13, 201998
NCT02445586Breast Neoplasms · India4CompletedSep 26, 201852
NCT02419742Breast Neoplasms · India4CompletedJun 24, 2021110
NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more3CompletedFeb 22, 2019418
NCT02005549Breast Neoplasms · Austria2CompletedApr 200818
NCT01862081Breast Neoplasms · United States, Belgium, Canada and more1CompletedJun 9, 201780
NCT00964704Breast Neoplasms2WithdrawnAug 20130
NCT00934856Breast Neoplasms · United States, France, Spain and more2CompletedOct 201398
NCT00927589Solid Cancers · United States1CompletedFeb 201359
NCT00845910Breast Neoplasms · Taiwan2TerminatedMay 201122
NCT00774241Breast Neoplasms4WithdrawnNov 20130
NCT00773695Breast Neoplasms · Norway2CompletedNov 9, 2022150
NCT00661778Carcinoma, Non-Small-Cell Lung · Spain2CompletedJul 201150
NCT00576901Breast Neoplasms · Spain2TerminatedJun 200923
NCT00559754Breast Neoplasms · Spain2CompletedSep 201072
NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more2CompletedSep 22, 2014417
NCT00127933Breast Neoplasms · United States4CompletedApr 2009157
NCT00077857Breast Neoplasms · United States, Bosnia and Herzegovina, China and more2CompletedMar 2010470

How it is read

Names in the registry

  • “Docetaxel”, 93 entries
  • “docetaxel”, 37 entries
  • “Taxotere”, 9 entries
  • “HB1801”, 8 entries
  • “Docetaxel for injection (Albumin-bound)”, 4 entries

Codes read as this program: CKD810.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.